Anticoagulation in Cardiovascular Diseases: Evolving role, unmet needs and grey areas

130K

views

146

authors

26

articles

Editorial

10 October 2023

Editorial: Anticoagulation in cardiovascular diseases: evolving role, unmet needs, and grey areas

Antonino Tuttolomondo

,

Pasquale Pignatelli

and

Roberto Pola

1,700 views

1 citations

Editors

3

Section Head of Internal Medicine and Thromboembolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore

Antonino Tuttolomondo

Dipartimento di Promozione della Salute, Medicina Materno-Infantile, Interna e Specialistica di Eccellenza G. D'Alessandro, Università degli Studi di Palermo

Pasquale Pignatelli

Sapienza University of Rome

Impact

Fetching...

About

Anticoagulant therapy has considerably evolved in the last few years, not only because of the availability of novel medications, such as the direct oral anticoagulants, but also because of the development of new clinical and therapeutic indications, which go beyond the classical prevention of cardioembolism in atrial fibrillation and the prevention and treatment of venous thromboembolism. An example of a novel indication is the prevention of new arterial events in subjects with ischemic cardiovascular diseases. If, on one hand, these new agents and indications have extended the use of anticoagulants to an ever-growing number of patients, on the other hand, there has been increasing appreciation that many unmet needs and several grey areas still exist in the field of anticoagulation.

The aim of this Research Topic is to increase our knowledge of the evolving role of anticoagulation in cardiovascular diseases, along with a better understanding of the controversial and unexplored issues that still exist in the arena of anticoagulant therapy.

We welcome original articles, reviews, and opinion papers on the role of anticoagulant therapy in the following areas:
1) Old and new anticoagulants.
2) Old and new indications to anticoagulation in cardiovascular medicine.
3) Anticoagulants for cancer-related thrombosis.
4) Anticoagulants for thrombosis in unusual sites.
5) Anticoagulants in COVID-19 patients and other infectious diseases.
6) Benefits and risks of anticoagulation in special populations (including, but not limited to, severe chronic kidney disease, extreme body weights, and patients with gastrointestinal resections).
7) The role of laboratory tests in guiding the use of direct oral anticoagulants.
8) Anticoagulants and chronic kidney disease.
9) Hemorrhagic stroke risk in traditional and novel anticoagulation.

Anticoagulant therapy has considerably evolved in the last few years, not only because of the availability of novel medications, such as the direct oral anticoagulants, but also because of the development of new clinical and therapeutic indications, which go beyond the classical prevention of cardioembolism in atrial fibrillation and the prevention and treatment of venous thromboembolism. An example of a novel indication is the prevention of new arterial events in subjects with ischemic cardiovascular diseases. If, on one hand, these new agents and indications have extended the use of anticoagulants to an ever-growing number of patients, on the other hand, there has been increasing appreciation that many unmet needs and several grey areas still exist in the field of anticoagulation.

The aim of this Research Topic is to increase our knowledge of the evolving role of anticoagulation in cardiovascular diseases, along with a better understanding of the controversial and unexplored issues that still exist in the arena of anticoagulant therapy.

We welcome original articles, reviews, and opinion papers on the role of anticoagulant therapy in the following areas:
1) Old and new anticoagulants.
2) Old and new indications to anticoagulation in cardiovascular medicine.
3) Anticoagulants for cancer-related thrombosis.
4) Anticoagulants for thrombosis in unusual sites.
5) Anticoagulants in COVID-19 patients and other infectious diseases.
6) Benefits and risks of anticoagulation in special populations (including, but not limited to, severe chronic kidney disease, extreme body weights, and patients with gastrointestinal resections).
7) The role of laboratory tests in guiding the use of direct oral anticoagulants.
8) Anticoagulants and chronic kidney disease.
9) Hemorrhagic stroke risk in traditional and novel anticoagulation.

Download ebook

Share

Editors

Section Head of Internal Medicine and Thromboembolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore

Antonino Tuttolomondo

Dipartimento di Promozione della Salute, Medicina Materno-Infantile, Interna e Specialistica di Eccellenza G. D'Alessandro, Università degli Studi di Palermo

Pasquale Pignatelli

Sapienza University of Rome

Impact

129,962 Total views

99,433 Article views

29,076 Article downloads

1,453 Topic views

Published In

Journal Thumbnail

Frontiers in Cardiovascular Medicine

Thrombosis and Haemostasis

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic